Ontario First in Canada to Provide Coverage for New ALS Treatment

Our government is giving people access to more treatment options by expanding public access to life-saving medication and therapeutics.

Expanding Ontario’s drug program to include Albrioza will ensure people living with ALS will benefit from this new treatment sooner and is another example of how our government is connecting more Ontarians to the care they need.

Albrioza is a new treatment option for those living with amyotrophic lateral sclerosis (ALS) also known as Lou Gehrig’s disease.

Ontario is the first jurisdiction in Canada to cover the new treatment through the Ontario Drug Benefit Program’s Exceptional Access Program.

Ontarians and their families are encouraged to reach out to their healthcare providers to help determine if Albrioza is a suitable treatment option for them.

Learn more: https://news.ontario.ca/en/release/1003213/ontario-first-in-canada-to-provide-coverage-for-new-als-treatment